Group A streptococcal vaccines: facts versus fantasy
- 1 December 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Infectious Diseases
- Vol. 22 (6), 544-552
- https://doi.org/10.1097/qco.0b013e328332bbfe
Abstract
This review provides an overview of progress of the development of group A streptococcal (GAS) vaccines with a focus on recent advances. Historically, GAS vaccine development has focused on the N-terminus of the M protein, which ultimately led to successful phase I/II clinical trials of a 26-valent recombinant M protein vaccine in 2004–2005. More recently, interest in antigens conserved among most, if not all, group A streptococci has increased. However, no vaccines containing these antigens have reached clinical trials. Three strategies have been used to develop conserved antigen vaccine candidates: use of the conserved region of the M protein; use of well described virulence factors as antigens, including streptococcal C5a peptidase, streptococcal carbohydrate, fibronectin-binding proteins, cysteine protease and streptococcal pili; and use of reverse vaccinology to identify novel antigens. Several vaccine candidates against GAS infection are in varying stages of preclinical and clinical development. Although there is great hope that one of these vaccine candidates will reach licensure in the next decade, only one, the multivalent N-terminal vaccine, has entered clinical trials in the last 30 years. Although strong advocacy for GAS vaccine development is important, there remains an urgent need to institute available public health control measures against GAS diseases globally, particularly in developing countries.Keywords
This publication has 96 references indexed in Scilit:
- Burden and Economic Cost of Group A Streptococcal PharyngitisPEDIATRICS, 2008
- The Epidemiology of Invasive Group A Streptococcal Infection and Potential Vaccine Implications: United States, 2000-2004Clinical Infectious Diseases, 2007
- The global burden of group A streptococcal diseasesThe Lancet Infectious Diseases, 2005
- Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult VolunteersClinical Infectious Diseases, 2005
- Prospects for a Group A Streptococcal Vaccine: Rationale, Feasibility, and Obstacles--Report of a National Institute of Allergy and Infectious Diseases WorkshopClinical Infectious Diseases, 2005
- Immunization against rheumatic feverThe Journal of Pediatrics, 1943
- Immunization against rheumatic fever with hemolytic streptococcus filtrateAmerican Heart Journal, 1940
- Immunization against rheumatic fever with hemolytic streptococcus filtrateAmerican Heart Journal, 1938
- INTRAVENOUS VACCINES OF HÆMOLYTIC STREPTOCOCCI IN ACUTE RHEUMATISM IN CHILDHOODThe Lancet, 1932
- INTRAVENOUS VACCINATION WITH HEMOLYTIC STREPTOCOCCIAmerican Journal of Diseases of Children, 1931